



10-13-05

1624\$✓
1FJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit 1624

In re

Patent Application of

David Edwin Thurston, et al.

Application No. 09/763,767

Confirmation No.: 6332

Filed: February 26, 2001

Examiner: Brenda Libby Coleman

"PYRROLOBENZODIAZEPINES"

I, Julie Mallder, hereby certify that this correspondence is being deposited with the US Postal Service in an envelope as "Express Mail Post Office to Addressee," Mailing Label No. EV 086437541 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Julie Mallder

Signature

October 12, 2005

Date of Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §1.97(c)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and PTO/SB/08B and copies of non-U.S. patent references are attached. This Statement is also being accompanied by a check in payment of the \$180.00 fee required under 37 CFR §1.17(p). Please charge or credit Deposit Account No. 50-0842 with any shortage or overpayment of the required fee.

Citation of these references is respectfully requested.


10/14/2005 HLE333 00000061 09763767

01 FC:1806

180.00 0P


No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,


Charlene L. Yager
Reg. No. 48,887

File No. 065435-9002

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
608.257.3501



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	1	of	1	Attorney Docket Number	065435-9002

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	EP	0239400A2	Winter, G.P.	9/30/1987		
	JP	53-82792	Microbiological Chemical Research	7/21/1978		
	WO	88/07378	Cancer Research Campaign Technology Ltd.	10/6/1988		
	WO	89/10140	Cancer Research Campaign Technology Ltd.	11/2/1989		
	WO	93/08288	Cancer Research Campaign Technology Ltd.	4/29/1993		
	WO	00/12506	The University of Portsmouth Higher Education Group	3/9/2000		
	WO	00/12507	The University of Portsmouth Higher Education Group	3/9/2000		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	1	of	8	Attorney Docket Number	065435-9002

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		ALBERICIO, F. et al., "NPE-Resin, A New Approach to the Solid-Phase Synthesis of Protected Peptides and Oligonucleotides II. Synthesis of Protected Peptides ^{1,2} ," <i>Tetrahedron Letters</i> , 32:1515-1518 (1991)
		ALBERICIO, F. et al., "NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides," <i>Peptides</i> 1990, Proc. 21.sub.st Eur. Pept. Symp., 134-136 (1990)
		ARISTOFF, J and JOHNSON, P., "Synthesis of CBI-PDE-I-Dimer, the Benzannelated Analogue of CC-1065," <i>J. Org. Chem.</i> , 57, 6234-6239 (1992)
		BAGSHAWE et al., "Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites," <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 4, 915-922 (1991)
		BAYLEY, H. et al., "Photoactivatable drugs," <i>TIPS</i> , 8, 138-143 (1987)
		BERRY, J. M. et al., "Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," <i>Tetrahedron Letters</i> , 41, 6171-6174 (2000)
		BOGER et al., "CC-1065 and the Duocarmycins: Synthetic Studies," <i>Chem. Rev.</i> , 97, 787-828 (1997)
		BOSE, D.S. et al., "Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System," <i>J. Am. Chem. Soc.</i> , 114, 4939-4941 (1992)
		BROWN, S.C. et al., "NMR Solution Structure of a Peptide Nucleic Acid Complexed with RNA," <i>Science</i> , 265, 777-780 (1994)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	2	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		BUNDGAARD, H., "Design and Application of Prodrugs," <i>A Textbook of Drug Design and Development</i> , eds Krogsgaard-Lassen, P., and Bundgaard, H., Harwood Academic Press, 113-135 (1991)
		BURGESS, K. et al., "Solid Phase Synthesis of Oligoureas", <i>J. Ame. Chem. Soc.</i> , 119: 1556-1564 (1997)
		BURGESS, K et al., "Solid Phase Synthesis of Unnatural Biopolymers Containing Repeating Urea Units," <i>Agnew Chem. Int. Ed. Engl</i> , 34, No. 8:907-909 (1995)
		CARRUTH, J.A.S., "Clinical applications for photodynamic therapy," <i>J. Photochem Photobiol.</i> , 9, 396-397 (1991)
		CHO, C Y et al., "An Unnatural Biopolymer", <i>Science</i> , 261: 1303-1305 (1993)
		CULVER et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," <i>Science</i> , 256, 1550-1552 (1992)
		DALTON, S. and TREISMAN, R, "Characterization of SAP-1, a Protein Recruited by Serum Response Factor to the c-fos Serum Response Element," <i>Cell</i> , 68, 597-612 (1992)
		DAMAYANTHI, Y., et al., "Design and synthesis of novel pyrrolo{2,1-c}[1,4] benzodiazepine-Lexitropsin Conjugates," <i>J. Org. Chem.</i> , 64, 290-292 (1999)
		DRESSMAN, B.A., et al., "Solid Phase Synthesis of Hydantoins Using a Carbamate Linker and a Novel Cyclization/Cleavage Step," <i>Tetrahedron Letters</i> , 37, 937-940 (1996)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	3	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		DROST, K.J. and CAVA, M.P., "A Photochemically Based Synthesis of the Benzannelated Analogue of the CC-1065 A Unit," <i>J. Org. Chem.</i> , 56:2240-2244 (1991)
		EASHOO, M. et al., "Fibers from a Low Dielectric Constant Fluorinated Polyimide: Solution Spinning and Morphology Control," <i>J. Polymer Science</i> , 35:173-185 (1997)
		EDMAN, P. and BEGG, G., "A Protein Sequenator," <i>Eur. J. Biochem.</i> , 1, 80-91 (1967)
		EGHOLM, M et al., "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," <i>J. Am. Chem. Soc.</i> , 114, 1895-1897 (1992)
		EGHOLM, M et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <i>Nature</i> , 365, 566-568 (1993)
		ENGLEHARDT et al., "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses," <i>Nature Genetics</i> , 4, 27-34 (1993)
		FIGLIOZZI, G.M. et al., "Synthesis of N-substituted Glycine Peptoid Libraries," <i>Methods in Enzymology</i> , 267: 437-447 (1996)
		FUJISAWA PHARMACEUTICAL CO. LTD., "Benzodiazepine derivatives," <i>SciFinder Scholar</i> , 2-3 (2002)
		FURKA, A. et al., "General method for rapid synthesis of multicomponent peptide mixtures," <i>Int. J. Peptide Protein Res.</i> , 37, 487-493 (1991)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	4	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		GARCIA-ECHEVERRIA, C., "A Base Labile Handle for Solid Phase Organic Chemistry", <i>Tetrahedron Letters</i> , 38,52, 8933-8934 (1997)
		GREENE, T.W. and WUTS, P.G.M., <i>Protective Groups in Organic Synthesis</i> , John Wiley & Sons, 2 nd ed., Ch 7, 315-345 (1991)
		HAUSKE, J. R. and DORFF, P., "Solid Phase CBZ Chloride Equivalent. A New Matrix Specific Linker", <i>Tetrahedron Letters</i> , 36, 10, 1589-1592 (1995)
		HOCART et al., "Highly potent cyclic disulfide antagonists of somatostatin," <i>J. of Medicinal Chem.</i> , 42:11 (1999)
		HOLMES, C.P. and JONES, D.G., "Reagents for Combinatorial Organic Synthesis: Development of a New O-Nitrobenzyl Photolabile Linker for Solid Phase Synthesis", <i>J. Org. Chem.</i> , 60, 2318-2319 (1995)
		HUBER, B. et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 88, 8039-8043 (1991)
		JENKINS, T.C. et al., "Structure of a Covalent DNA Minor Groove Adduct with a Pyrrolobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand Cross-Linking," <i>J. Med. Chem.</i> , 37, 4529-4537 (1994)
		JUNGHEIM, L.N. and SHEPHERD, T.A., "Design of Antitumor Prodrugs: Substrates for Antibody Targeted Enzymes," <i>Am. Chem. Soc. Chem. Rev.</i> , 94, 1553-1566 (1994)
		KAPOOR, T.M. et al., "Exploring the Specificity Pockets of Two Homologous SH3 Domains Using Structure-Based, Split-Pool Synthesis and Affinity-Based Selection," <i>J. Am. Chem. Soc.</i> 120:23-29 (1998)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	5	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		KENNEDY, J.C. and POTTIER, R.H., "Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy," <i>J. Photochem Photobiol</i> , 14, 275-292 (1992)
		KUNZ, H. and DOMBO, B., "Solid Phase Synthesis of Peptide and Glycopeptides on Polymeric Supports with Allylic Anchor Groups," <i>Angew Chem. Int. Ed. Engl</i> , 5, 711-713 (1988)
		KUZMICH, S. et al., "Increased levels of glutathione S-transferase π transcript as a mechanism of resistance to ethacrynic acid," <i>Journal of Biochemistry</i> , 281, 219-224 (1992)
		LESCRINIER, T. et al., "DNA-Binding Ligands from Peptide Libraries Containing Unnatural Amino Acids," <i>Chem. Eur. J.</i> , 4, 3, 425-433 (1998)
		LEWIS A.D. et al., "Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects," <i>Carcinogenesis</i> , 9, 1283-1287 (1988)
		LOWN et al., "Molecular Mechanism of Binding of Pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid - anthramycin and tomaymycin," <i>Biochem. Pharmacol.</i> (1979), 28 (13), 2017-2026; and Abstract No. 51709
		MIZUSHIMA, S. and NAGATA, S., "pEF-BOS, a powerful mammalian expression vector," <i>Nucl. Acids Res.</i> , 18, 5322 (1990)
		MONKS, A. et al., "Feasibility of High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines," <i>Journal of National Cancer Institute</i> , 83, 757-766 (1991)
		MORAN, E.J. et al., "Novel Biopolymers for Drug Discovery: Biopolymers", <i>Peptide Science</i> , John Wiley and Sons, 37: 213-19 (1995)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	6	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		MORGAN, R.A. and ANDERSON, W.F., "Human Gene Therapy," <i>Annu. Rev. Biochem.</i> , 62, 191-217 (1993)
		MOSMANN, T., "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <i>J. Immunological Methods</i> , 65, 55-63 (1983)
		MULLEN, D.G. and BARANY, G., "A New Fluoridolizable Anchoring Linkage for Orthogonal Solid-Phase Peptide Synthesis: Design, Preparation, and Application of the N-(3 or 4)-[[4-(Hydroxymethyl) phenoxy]-tert-butylphenylsilyl]phenyl Pentanedioic Acid Monoamide (Pbs) Handle", <i>J. Org. Chem.</i> , 53, 5240-5248 (1988)
		NICOLAOU, K.C. et al., "Designed Eneclaynes: A New Class of DNA-Cleaving Molecules with Potent and Selective Anticancer Activity," <i>Science</i> , 256, 1172-1178 (1992)
		NIELSON, P.E. et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," <i>Science</i> , 254, 1497-1500 (1991)
		O'NEIL, I.A., et al., "The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines," <i>Synlett</i> , 75-78 (1997)
		PAIKOFF, S.J. et al., "The Solid Phase Synthesis of N-Alkylcarbamate Oligomers", <i>Tetrahedron Letters</i> , 37, No. 32: 5653-5656 (1996)
		PILLAI, V.N.R., "Photoremovable protecting groups in organic chemistry," <i>Synthesis</i> , 1-26 (1980)
		RAM, Z. et al., "In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats," <i>Cancer Research</i> , 53, 83-88 (1993)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	7	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		RAWAL, V.H. et al., "Photocyclization Strategy for the Synthesis of Antitumor Agent CC-1065: Synthesis of Dideoxy PDE-I and PDE-II. Synthesis of Thiophene and Furan Analogues of Dideoxy PDE-I and PDE-II," <i>J. Org. Chem.</i> , 52, 19-28 (1987)
		REGULA, J. et al., "Photosensitisation and photodynamic therapy of oesophagael, duodenal and colorectal tumours using 5-aminolevulinic acid induced photoporphyrin IX-a pilot study," <i>Gut</i> , 36, 67-75 (1995)
		SAGNOU, M.J. et al., "Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT," <i>Bioorganic & Medicinal Chemistry Letters</i> , 10, 2083-2086 (2000)
		SAHA, A.K. et al., "Diisopropylsilyl-Linked Oligonucleotide Analogs: Solid-Phase Synthesis and Physicochemical Properties," <i>J. Org. Chem.</i> , 58, 7827-7831 (1993)
		SATYAM, A. et al., "Design, Synthesis, and Evaluation of Latent Alkylating Agents Activated by Glutathione S-Transferase," <i>J. Med. Chem.</i> , 39, 1736-1747 (1996)
		SIMON, R.J. et al., "Peptoids: A Modular Approach to Drug Discovery", <i>Proc. Natl. Acad. Sci. USA</i> , 89:9367-9371 (1992)
		SOTH, M.J. and NOWICK, J.S., "Unnatural oligomers and unnatural oligomer libraries", <i>Curr. Opin. Chem. Biol.</i> , 1:120-129 (1997)
		STAR, W.M., "Light delivery and light dosimetry for photodynamic therapy," <i>Lasers in Medical Science</i> , 5:107-113 (1990)
		TEW, K.D. and CLAPPER, M.L., "Glutathione-S-transferase and anti-cancer drug resistance," <i>Mechanism of Drug Resistance in Neoplastic Cells</i> , Woolley, P.V. and Tew, K.D., Eds, Academic Press: Sand Diego, CA 141-159 (1988)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/763,767
				Filing Date	February 26, 2001
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	Brenda Libby Coleman
Sheet	8	of	8	Attorney Docket Number	065435-9002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		UMEZAWA, H. et al., "Mazethramycins," <i>SciFinder Scholar</i> , 2-3 (2002)
		ZUCKERMAN, R.N. et al., "Discovery of Nanomolecular Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted) glycine Peptoid Library", <i>J. Med. Chem.</i> , 37:2678-2685 (1994)
		<i>Dictionary of Science and Technology</i> , Professor P.M.B. Walker ed. Larousse plc., pp. 63, 457, 523 (1995)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.